Atara Biotherapeutics is a company that provides allogeneic T-cell immunotherapy solutions. It offers investigational therapies that target various diseases caused by Epstein-Barr virus (EBV), such as post-transplant lymphoproliferative disease (PTLD), multiple sclerosis (MS), and mesothelioma. The company also delivers a platform that is used to develop chimeric antigen receptor T (CAR T) and AlloCAR T therapies for other non-EBV-associated diseases.